Cargando…

Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer

Ga-68 Prostate-Specific Membrane Antigen PET/CT is a new tool for the assessment of prostate cancer. Standard imaging time is 60 minutes post injection of radiotracer. At 60 minutes, there is physiologic accumulation of radiotracer in the urinary bladder which may cause some lesions in its vicinity...

Descripción completa

Detalles Bibliográficos
Autores principales: Barakat, Andrew, Yacoub, Basel, Homsi, Maria El, Saad Aldine, Amro, El Hajj, Albert, Haidar, Mohamad B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026091/
https://www.ncbi.nlm.nih.gov/pubmed/32066750
http://dx.doi.org/10.1038/s41598-020-59296-6
_version_ 1783498617836797952
author Barakat, Andrew
Yacoub, Basel
Homsi, Maria El
Saad Aldine, Amro
El Hajj, Albert
Haidar, Mohamad B.
author_facet Barakat, Andrew
Yacoub, Basel
Homsi, Maria El
Saad Aldine, Amro
El Hajj, Albert
Haidar, Mohamad B.
author_sort Barakat, Andrew
collection PubMed
description Ga-68 Prostate-Specific Membrane Antigen PET/CT is a new tool for the assessment of prostate cancer. Standard imaging time is 60 minutes post injection of radiotracer. At 60 minutes, there is physiologic accumulation of radiotracer in the urinary bladder which may cause some lesions in its vicinity to be obscured. Our aim is to determine if early imaging at 3 minutes in addition to standard imaging at 60 minutes can improve the detection of PSMA-avid lesions. A retrospective review of 167 consecutive patients was conducted. Overall, 115 patients (68.9%) were ruled to have prostate cancer based on imaging as seen on early or standard PET/CT images. In 106/115 (64%), the lesions were detected on both early and standard imaging; in 8/115 (6.9%), the lesions were only detected on early imaging; in 1/115 (0.6%) the lesion was detected only on standard imaging. The addition of early imaging significantly improved the overall detection rate of PSMA-avid lesions (p = 0.039). The ratio of patients with lesions detected on early imaging but not on standard imaging in restaging group was 7/88 and was higher than that in staging group 1/79 (p = 0.043). We recommend early imaging in addition to the standard imaging in Ga-68 PSMA PET/CT, particularly in patients presenting for restaging of prostate cancer.
format Online
Article
Text
id pubmed-7026091
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70260912020-02-24 Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer Barakat, Andrew Yacoub, Basel Homsi, Maria El Saad Aldine, Amro El Hajj, Albert Haidar, Mohamad B. Sci Rep Article Ga-68 Prostate-Specific Membrane Antigen PET/CT is a new tool for the assessment of prostate cancer. Standard imaging time is 60 minutes post injection of radiotracer. At 60 minutes, there is physiologic accumulation of radiotracer in the urinary bladder which may cause some lesions in its vicinity to be obscured. Our aim is to determine if early imaging at 3 minutes in addition to standard imaging at 60 minutes can improve the detection of PSMA-avid lesions. A retrospective review of 167 consecutive patients was conducted. Overall, 115 patients (68.9%) were ruled to have prostate cancer based on imaging as seen on early or standard PET/CT images. In 106/115 (64%), the lesions were detected on both early and standard imaging; in 8/115 (6.9%), the lesions were only detected on early imaging; in 1/115 (0.6%) the lesion was detected only on standard imaging. The addition of early imaging significantly improved the overall detection rate of PSMA-avid lesions (p = 0.039). The ratio of patients with lesions detected on early imaging but not on standard imaging in restaging group was 7/88 and was higher than that in staging group 1/79 (p = 0.043). We recommend early imaging in addition to the standard imaging in Ga-68 PSMA PET/CT, particularly in patients presenting for restaging of prostate cancer. Nature Publishing Group UK 2020-02-17 /pmc/articles/PMC7026091/ /pubmed/32066750 http://dx.doi.org/10.1038/s41598-020-59296-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Barakat, Andrew
Yacoub, Basel
Homsi, Maria El
Saad Aldine, Amro
El Hajj, Albert
Haidar, Mohamad B.
Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer
title Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer
title_full Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer
title_fullStr Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer
title_full_unstemmed Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer
title_short Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer
title_sort role of early pet/ct imaging with 68ga-psma in staging and restaging of prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026091/
https://www.ncbi.nlm.nih.gov/pubmed/32066750
http://dx.doi.org/10.1038/s41598-020-59296-6
work_keys_str_mv AT barakatandrew roleofearlypetctimagingwith68gapsmainstagingandrestagingofprostatecancer
AT yacoubbasel roleofearlypetctimagingwith68gapsmainstagingandrestagingofprostatecancer
AT homsimariael roleofearlypetctimagingwith68gapsmainstagingandrestagingofprostatecancer
AT saadaldineamro roleofearlypetctimagingwith68gapsmainstagingandrestagingofprostatecancer
AT elhajjalbert roleofearlypetctimagingwith68gapsmainstagingandrestagingofprostatecancer
AT haidarmohamadb roleofearlypetctimagingwith68gapsmainstagingandrestagingofprostatecancer